MDGL Q1 2022 Earnings — Madrigal Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

MDGLMadrigal Pharmaceuticals, Inc.

$10B

Q1 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$58M

Net Income

-$58M

EPS (Diluted)

$-3.36

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$50M

Free Cash Flow

-$50M

Stock-Based Comp.

$7M

Balance Sheet

Total Assets

$223M

Total Liabilities

$77M

Stockholders' Equity

$146M

Cash & Equivalents

$42M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$58M	-$53M	-8.7%
Net Income	-$58M	-$53M	-9.5%